120511-73-1
- Product Name：Anastrozole
- Molecular Formula：C17H19N5
- Purity：99%
- Molecular Weight：
Product Details
Appearance:crystalline solid
Hot Sale! Anastrozole 120511-73-1 supplier, good producer.
- Molecular Formula:C17H19N5
- Molecular Weight:293.371
- Appearance/Colour:crystalline solid
- Melting Point:81 - 82 °C
- Refractive Index:1.791
- Boiling Point:469.718 °C at 760 mmHg
- PKA:2.62±0.10(Predicted)
- Flash Point:237.877 °C
- PSA：78.29000
- Density:1.085 g/cm3
- LogP:2.92876
Anastrozole 120511-73-1 Usage
Anastrozole, chemically known as 2,2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropiononitrile) a derivative of benzotriazole with the CAS registry number 120511-73-1, is used to treat early hormone receptor-positive breast cancer. It is also used for first-line treatment of hormone receptor-positive or hormone receptor-unknown advanced or metastatic (cancer that has spread) breast cancer. Anastrozole has been demonstrated to increase T concentrations and the T/E ratio (9). A small but growing number of studies support the efficacy of aromatase inhibition in the treatment of hypoandrogenic subfertile men 10, 11, 12, 13, 14. It is considered to be second-line therapy (after tamoxifen) in the treatment of postm enopaus al breast cancer.
Definition
ChEBI: Anastrozole is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile.
InChI:InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
120511-73-1 Relevant articles
The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials
Osama Alomar MD , Kehinde S. Okunade MBBS , Hamed Kord Varkaneh PhD , Ghada Ghourab MD , Jouri Ahmed Alsourani , Kamar Allayl Alras MBBS , Mohd Diya Masmoum MBBS , Aya Alfardous Alazm MBBS , Ismail A. Al-Badawi MD, FRCSC , Hany Salem MD , Ahmed Abu-Zaid MBBS
Clinical Therapeutics Volume 44, Issue 9, September 2022, Pages 1214-1224
We aimed to investigate the impact of anastrozole administration on the traditional components of the lipid profile (ie, total cholesterol [TC], LDL-C, HDL-C, and triglycerides [TGs]) by means of a systematic review and meta-analysis of randomized controlled trials.
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
Prof Jack Cuzick, PhD Ivana Sestak, PhD Prof John F Forbes, MD Prof Mitch Dowsett, PhD Simon Cawthorn, MD Robert E Mansel, MD
The lancet, 2020
3864 women were recruited between Feb 2, 2003, and Jan 31, 2012. 1920 women were randomly assigned to 5 years anastrozole and 1944 to placebo. After a median follow-up of 131 months (IQR 105–156), a 49% reduction in breast cancer was observed for anastrozole (85 vs 165 cases, hazard ratio [HR] 0·51, 95% CI 0·39–0·66, p<0·0001). The reduction was larger in the first 5 years (35 vs 89, 0·39, 0·27–0·58, p<0·0001), but still significant after 5 years (50 vs 76 new cases, 0·64, 0·45–0·91, p=0·014), and not significantly different from the first 5 years (p=0·087). Invasive oestrogen receptor-positive breast cancer was reduced by 54% (HR 0·46, 95% CI 0·33–0·65, p<0·0001), with a continued significant effect in the period after treatment.
Anastrozole Regulates Fatty Acid Synthase in Breast CancerAnastrozole Regulates FASN mRNA and Protein
Junmei Cairns; James N. Ingle ; Krishna R. Kalari; Matthew P. Goetz ; Richard M. Weinshilboum; Huanyao Gao ; Hu Li; Mehrab Ghanat Bari; Liewei Wang
Mol Cancer Ther (2022) 21 (1): 206–216.
We demonstrate that anastrozole, through its binding to ER, directly represses gene transcription that is responsible for FASN protein degradation in breast cancer cells. We further show that increased FASN protein activates ERα, negatively affecting its own expression.
120511-73-1 Upstream products
-
120511-91-3
α,α,α',α'-tetramethyl-5-chloromethyl-1,3-benzene diacetonitrile
-
1015083-81-4
anastrozole mesylate
-
120511-84-4
2-[3-bromomethyl-5-(cyanodimethylmethyl)phenyl]-2-methylpropanenitrile
-
41253-21-8
sodium triazole
120511-73-1 Downstream products
-
1015083-81-4
anastrozole mesylate
-
120511-72-0
3,5-bis(2-cyanoprop-2-yl)toluene
Relevant Products
-
Cyclopropane, isocyanato- 4747-72-2CAS：4747-72-2
-
ImidocarbCAS：27885-92-3
-
Tetrahydrophthalic AnhydrideCAS：85-43-8
